Clinical Trials Logo

Metastatic Uveal Melanoma clinical trials

View clinical trials related to Metastatic Uveal Melanoma.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02697630 Completed - Clinical trials for Metastatic Uveal Melanoma

Efficacy Study of Pembrolizumab With Entinostat to Treat Metastatic Melanoma of the Eye

PEMDAC
Start date: February 21, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to see if the combination of entinostat and pembrolizumab can be an effective treatment for patients with melanoma of the eye (uveal melanoma) that has spread to other sites of the body (metastatic disease). Pembrolizumab is an antibody that helps the immune system to attack cancer cells. Although pembrolizumab has proven clinical efficacy in treating patients with metastatic cutaneous melanoma, an effect on metastatic uveal melanoma has not been established. Entinostat is a histone deacetylase (HDAC) inhibitor that has effects on both cancer cells and immune regulatory cells, thus potentially enhancing the effects of immunotherapy.

NCT ID: NCT01551459 Completed - Clinical trials for Metastatic Uveal Melanoma

A Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma

SUAVE
Start date: October 2010
Phase: Phase 2
Study type: Interventional

Doctors usually treat uveal melanoma with radiotherapy or surgery. But if this cancer spreads, it is more difficult to treat. Doctors usually treat uveal melanoma that has spread with a chemotherapy called dacarbazine, but they are always looking to find new ways to treat uveal melanoma. This study aims to find out how well Sunitinib works to treat uveal melanoma and to see how long Sunitinib and Dacarbazine can help to prevent the cancer from getting worse.